Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration of topical tacrolimus with other immunosuppressive agents may potentiate the immunosuppressive effects of topical tacrolimus. However, data concerning its safety and efficacy in combination with immunosuppressants are not available. According to the prescribing information, rare cases of skin malignancy and lymphoma have been reported in patients who have received treatment with topical calcineurin inhibitors, including topical tacrolimus. On the other hand, systemic exposure from topical tacrolimus is reported to be less than 1 ng/mL. In addition, the lowest tacrolimus blood concentration from topical application at which systemic effects can be observed is unknown.

MANAGEMENT: According to the manufacturer, use of topical tacrolimus in immunocompromised patients is not recommended. Therefore, until further information is available, it may be advisable to avoid its concomitant use with other immunosuppressants. Screening for the development of malignancy during and after treatment may also be considered.

Food may interfere with the absorption of ixazomib, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take ixazomib at least 1 hour before or 2 hours after eating. On days when you take both ixazomib and dexamethasone, make sure you do not take them at the same time, since ixazomib should be taken on an empty stomach while dexamethasone should be taken with food to prevent irritation and injury to the stomach.